Английская Википедия:EXS4318

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Orphan

EXS4318 is a selective PKC theta inhibitor that is potentially first-in-class medication. Developed by Exscientia, it was licensed to Bristol Myers Squibb.[1][2] In 2023, it entered clinical trials in humans.[3]

References

Шаблон:Reflist